The US Food and Drug Administration approved an injectable drug, Nucala from GlaxoSmithKline to treat severe asthma attacks.
The drug has been approved to treat patients 12 years and older who cannot control their asthma with more conventional drug options.
Nucala will be administered once every four weeks by subcutaneous injection into the upper arm, thigh, or abdomen.
Patients are advised to take other medications, including high-dose inhaled corticosteroids and at least one additional asthma drug.
The side effects of the drug include headache, injection site reactions, back pain, and fatigue. Hypersensitivity reactions can occur within hours or days of injection with Nucala.